$KVUE Balance Sheet | Understand Stock

$KVUE

$19.50 -$0.07 (0.36%) Close

$KVUE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD; shares in millions, except per-share amounts

	Q2 FY2026 As of Jun 28, 2026	Q1 FY2026 As of Mar 29, 2026	Q4 FY2025 As of Dec 28, 2025	Q3 FY2025 As of Sep 28, 2025	Q2 FY2025 As of Jun 29, 2025	Q1 FY2025 As of Mar 30, 2025	Q4 FY2024 As of Dec 29, 2024	Q3 FY2024 As of Sep 29, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Oct 1, 2023	Q2 FY2023 As of Jul 2, 2023	Q1 FY2023 As of Apr 2, 2023
Assets
Current assets
Cash and cash equivalents
Trade receivables, less allowances for credit losses ($18 and $26 as of June 28, 2026 and December 28, 2025, respectively)
Inventories
Prepaid expenses and other receivables
Other current assets
Total current assets
Property, plant, and equipment, net
Intangible assets, net
Goodwill
Deferred taxes on income
Restricted cash
Other assets
Total Assets

Liabilities and Stockholders’ Equity
Current liabilities
Loans and notes payable
Accounts payable
Accrued liabilities
Accrued rebates, returns, and promotions
Accrued taxes on income
Total current liabilities
Total long-term debt
Deferred taxes on income
Employee-related obligations
Other liabilities
Liabilities, Total
Stockholders’ Equity
Preferred stock, $0.01 par value, 750,000 shares authorized; no shares issued and outstanding as of June 28, 2026 and December 28, 2025
Common stock, $0.01 par value, 12,500,000 shares authorized; 1,940,628 and 1,920,241 shares issued and outstanding as of June 28, 2026, respectively; 1,936,502 and 1,916,115 shares issued and outstanding as of December 28, 2025, respectively
Additional paid-in capital
Treasury stock, 20,387 and 20,387 shares at cost as of June 28, 2026 and December 28, 2025, respectively
Accumulated deficit
Net investment from Johnson & Johnson
Accumulated other comprehensive loss
Total stockholders’ equity
Total Liabilities and Stockholders’ Equity
Treasury stock, at cost (in shares)
Preferred stock, par value (in dollars per share)
Preferred stock outstanding (in shares)
Preferred stock issued (in shares)
Preferred stock authorized (in shares)
Common stock authorized (in shares)

Comments